Everolimus for Retinal Astrocytic Hamartomas in Tuberous Sclerosis Complex

Ophthalmol Retina. 2018 Mar;2(3):257-260. doi: 10.1016/j.oret.2017.08.005. Epub 2017 Oct 12.

Authors

Sara Marciano¹, Maria Giulia Mutolo², Martina Siracusano¹, Romina Moavero¹, Paolo Curatolo¹, Leonardo Emberti Gialloreti³

Affiliations

¹ Department of System Medicine, Pediatric Neurology Unit, University of Rome Tor Vergata, Rome, Italy.
² Ophthalmology Unit, Sant'Andrea Hospital, NESMOS Department, University of Rome "Sapienza", Rome, Italy.
³ Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy; "Francesca Benassi" Research Centre, Rome, Italy. Electronic address: leonardo.emberti.gialloreti@uniroma2.it.

PMID: 31047596
DOI: 10.1016/j.oret.2017.08.005

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Everolimus / therapeutic use*
Fluorescein Angiography
Fundus Oculi
Hamartoma / complications
Hamartoma / diagnosis
Hamartoma / drug therapy*
Humans
Immunosuppressive Agents / therapeutic use
Retinal Pigment Epithelium / pathology*
Tomography, Optical Coherence
Tuberous Sclerosis / complications*
Tuberous Sclerosis / diagnosis
Tuberous Sclerosis / drug therapy

Substances

Immunosuppressive Agents
Everolimus